{"id":"NCT01041859","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","briefTitle":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy","officialTitle":"A Randomized-Withdrawal, Placebo-Controlled, Study Evaluating the Efficacy, Safety, and Tolerability of Tapentadol Extended-Release (ER) in Subjects With Chronic, Painful Diabetic Peripheral Neuropathy (DPN)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-12","primaryCompletion":"2011-03","completion":"2011-03","firstPosted":"2010-01-01","resultsPosted":"2012-05-14","lastUpdate":"2013-09-11"},"enrollment":460,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Peripheral Neuropathy"],"interventions":[{"type":"DRUG","name":"Tapentadol extended release (ER)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tapentadol Extended Release (ER)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy, safety, and tolerability of orally administered tapentadol extended release (ER) at dosages of 100 to 250 mg twice daily compared with placebo in patients with moderate to severe pain due to chronic, painful diabetic peripheral neuropathy (DPN) who tolerated tapentadol (ER) and have an initial treatment effect (pain improvement) after a 3-week, open-label titration period.","primaryOutcome":{"measure":"Change From Double-Blind Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12","timeFrame":"Double-Blind Baseline and 12 weeks (Primary endpoint is the average pain intensity score during the last week of the maintenance period)","effectByArm":[{"arm":"DB Tapentadol ER","deltaMin":0.28,"sd":2.04},{"arm":"DB Placebo","deltaMin":1.3,"sd":2.43}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":72,"countries":["United States","Canada","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":459},"commonTop":["Nausea","Dizziness","Vomiting","Constipation","Somnolence"]}}